Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Lymphoma, Large B-Cell, Diffuse

dichlororibofuranosylbenzimidazole has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lam, LT1
Pickeral, OK1
Peng, AC1
Rosenwald, A1
Hurt, EM1
Giltnane, JM1
Averett, LM1
Zhao, H1
Davis, RE1
Sathyamoorthy, M1
Wahl, LM1
Harris, ED1
Mikovits, JA1
Monks, AP1
Hollingshead, MG1
Sausville, EA1
Staudt, LM1

Other Studies

1 other study available for dichlororibofuranosylbenzimidazole and Lymphoma, Large B-Cell, Diffuse

ArticleYear
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
    Genome biology, 2001, Volume: 2, Issue:10

    Topics: Antineoplastic Agents; Dactinomycin; Dichlororibofuranosylbenzimidazole; Flavonoids; Gene Expression

2001